News Release

Serial ketamine infusions for treatment-resistant bipolar depression

Peer-Reviewed Publication

JAMA Network

About the Study: In TRBD, adjunctive IV ketamine was well tolerated and associated with significant antidepressant effects compared to midazolam.

Corresponding Author: Joshua D. Rosenblat, MD, MSc, University Health Network, 399 Bathurst St, Main Pavilion 7-424, Toronto, ON M5T 2S8, Canada (joshua.rosenblat@uhn.ca)

10.1001/jamapsychiatry.2026.2658

To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.2658?guestAccessKey=6b47e245-a59e-40bb-88f8-eee95ac966ed&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090226

 

Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.